Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in LDLT for HCC Exceeding Milan Criteria
NCT01374750Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- May 2010
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sirolimus in hepatocellular carcinoma (HCC) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Recurrence-Free Survival at 3 years. Started May 2010; status: completed.
02
Drugs
sirolimus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01374750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01374750.